Sandoz receives approvals in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal® Forspiro®

  • Regulatory authorities in Ireland and Czech Republic grant marketing authorizations for AirFluSal® Forspiro®
  • Approval for 50-250 and 50-500µg dosage forms
  • AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, November 19, 2014 – Sandoz announces today that the pharmaceutical regulatory authorities in Ireland and the Czech Republic have granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

…

/by

Sandoz commits to increasing patient access to important respiratory treatments

November 19, 2014 – Today, on World Chronic Obstructive Pulmonary Disease (COPD) Day, Sandoz reaffirms its commitment to providing needed treatments for respiratory conditions such as COPD. COPD is a progressive disease that makes it hard to breathe, with symptoms that can affect aspects of everyday life1,2.

The most common symptoms of COPD include shortness of breath, abnormal sputum production, a chronic cough, wheezing and chest tightness4. Daily activities, such as walking up a short flight of stairs, can become very difficult as the condition …

/by

Global health challenges – including life expectancy – are influenced by gender

November 19, 2014 – The health challenges facing both men and women globally are heavily influenced by gender. Today, International Men’s Day, the global health community seeks to promote positive male role models, celebrate men’s positive contributions to society, focus on men’s health and wellbeing, highlight discrimination against males, and improve gender relations and promote gender equality.

Globally, men die younger than women. There are a number of reasons for this, such as biological, societal and behavioral differences.

Gender differences in health …

/by